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ABSTRACT
Glutathione s-transferases (GSTs) are the vital enzymes involved in Phase II metabolism to detoxify a wide range 
of carcinogenic metabolites in the body. GST class mu-1 (GSTM1) and GST class theta-1 (GSTT1) are the genes 
encoding for the GST isoenzymes. Nevertheless, both genes were frequently reported absent  (null) in most of the 
populations at different frequencies. Null polymorphism will affect the production of GSTs and impair the ability to 
eliminate carcinogenic compounds which had been shown to expose null individuals to high risk of several cancers 
such as gastric and lung cancer. Thus, this review will briefly summarize on the GSTM1 and GSTT1 polymorphisms, 
frequencies of null variants in populations worldwide, including Malaysian, and their relevancy to the underlying 
basis of toxicological response to xenobiotics. Additionally, the genotyping assays used in GST studies will also be 
discussed.
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INTRODUCTION
Phase II metabolism is part of the sequential phases in 
drug metabolism system, providing the cellular defense 
against genotoxic molecules introduced into the body 
(1). Amongst all enzymatic systems constructing the 
metabolic pathway, Glutathione-s-transferase (GSTs) are 
the main powerhouse to perform biotransformation or 
detoxification of harmful substances and to reduce the 
genotoxicity in the body (2). Low substrate specificity of 
the GST binding sites also enables the enzyme to tackle 
a wide range of compounds that can be divided into two 
types: endobiotics (natively present in human body) and 
xenobiotics (present in the environment) (2).
GST-encoding genes, GST mu class 1 (GSTM1) and 
GST theta class 1 (GSTT1) have been frequently 
observed  absent in most of the human populations. 
GSTM1 absents in approximately 50% of Caucasian 
and Asian populations, and 30% in African descents 
(3). In contrast, the prevalence of GSTT1 deletion 
is substantially higher in Asians (41%) and lower in 
Caucasians and Africans with only 20% (3). Thus, these 
have gradually placed GSTs in a broader scope as the 
null genotype  has been widely reported across various 
populations, suggesting the genetic polymorphisms 
are dependent on geographical and ethnic/population 
factors (2). Loss of the gene functions will alter the 
expression and functionality of the enzymes and depicts 
the inter-individual variability in the detoxification 
system (4). Genetic polymorphism also triggers the onset 
of various diseases including carcinogenic diseases such 
as colorectal, prostate, lung, and bladder cancer under 
the exposure of highly reactive compounds (5–8).
Conventional polymerase chain reaction (PCR) method 
such as multiplex PCR is commonly used to genotype 
both genes simultaneously (9). However, the method 
is only limited to determination of homozygous null 
genotype and unable to discriminate heterozygosity 
which can be performed by advanced and quantitative 
assays such as combination long-range PCR and 
real-time PCR (10,11). Therefore, the recent state of 
knowledge encompassing the prevalence of both 
GSTM1 and GSTT1 polymorphism among  various 
populations includes Malaysian, consequences of the 
polymorphisms toward risk of  diseases and appropriate 
genotyping assays  are discussed  in detail here.
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OVERVIEW
Glutathione s-transferases: Definition and 
multifunctionality
In xenobiotic or drug metabolic pathway, GSTs are 
the key player in the detoxification of both xenobiotics 
and endogenous reactive products of cellular metabo-
lism. These enzymes are responsible to conjugate the 
hydrophobic reactive compounds to reduced glutathi-
one (GSH) (12). GSTs promote a nucleophilic attack of 
sulphur atom of the tripeptide GSH on the electrophilic 
group of the compounds to form less reactive and hy-
drophilic products. The products are later readily to be 
eliminated by Phase 3 enzymes (12,13). 
Apart from its role in detoxification, GSTs are able to pro-
tect body tissue from oxidative damages. GSTs also serve 
as peroxidases which conjugate GSH to the endogenous 
products of lipid peroxidation such as epoxides, alkenes 
and aldehydes (14). In addition, cytosolic GSTs exhibit 
the properties of isomerase activity that aids the conver-
sion of metabolites or compounds to a more stable form 
such as the production of prostaglandins (PGD2, PGE2, 
and PGF2α) in the eicosanoid pathway, which are im-
portant in regulation of body temperature, production of 
hormone and prevention of platelet aggregation (15,16). 
Non-catalytic binding region on the GSTs allows the en-
zymes to function as a ligandin that regularly transports 
endogenous compounds such as bile salts, heme, and 
bilirubin to avoid excessive accumulation of molecules 
in the membrane or within the cell (17). These discov-
eries on the functions of GST marked the importance of 
the enzymes in body metabolism and human wellness.
GST superfamilies
Glutathione s-transferases (GSTs) isoenzymes are clas-
sified into two distinct superfamilies (13). The larger su-
perfamily is composed of cytosolic or soluble enzymes, 
which have at least 16 genes that encode proteins with 
GST activity in tissue cytosols and sub classified into 
eight classes as shown in Figure 1 (2,18). Classification 
of the GST genes into different classes was based on the 
degree of sequence identity. Each gene in the same GST 
class exhibit more than 60% sequence similarity be-
tween each other but showing less than 25% similarity 
with the genes from other GST classes (19). In compar-
ison to other seven classes, GSTK is frequently found 
in mitochondria compared to cytoplasm in soluble state 
(20). Additionally, GSTM has the most complex struc-
ture among the classes as there are a cluster of five genes 
located on chromosome 1 (19). Unlike GSTM, other 
classes such as GSTZ and GSTP have simpler structure 
due to only a single gene present in each class (21,22). 
Meanwhile, the other superfamily is microsomal GSTs 
that are categorized as membrane associated proteins 
in eicosanoid and glutathione metabolism (MAPEG) and 
comprised of at least six genes (Fig. 1) (23,24). Micro-
somal GSTs possess diverse functions such as leukot-
riene biosynthesis and cytoprotection by exhibiting glu-
tathione s-transferase and peroxidase activities (18,24). 
Among these two superfamilies, cytosolic GSTs (GSTA, 
GSTK, GSTM, GSTT, and GSTO) are the main proteins 
in detoxifying xenobiotics and endobiotics as they are 
extensively expressed in the liver (i.e. the major organ 
for detoxification) (18).
Genetic Polymorphism of GSTs and Their Relevancy
Genetic polymorphism can be referred as the existence 
of DNA sequence variants in a population at a mini-
mum rate of 1% (25). It arises from any mutations in 
normal DNA segment that are mainly caused by unre-
paired DNA damage and deletion or insertion in certain 
nucleotide sequences due to mobile genetic elements 
(26). These events may provoke a point mutation where 
the mutated variant is different from the normal nucleo-
tide sequence in a single nucleotide base (single nucle-
otide polymorphisms (SNPs)) as well as alteration of the 
whole chromosomal structure by translocation, dele-
tion, duplication or inversion of a certain chromosomal 
region (26).
Mutations in DNA sequences that encoding for import-
ant organs and working body systems may impair and 
modify human physiological system (27). Chances of 
the mutations to occur are varying among individuals 
and may lead to inter-individual difference in health and 
development process (27). In view of detoxification sys-
tem, variations in the genes encoding GSTs may have 
the potential to cause alteration and dysfunction of the 
enzymes that affect the xenobiotic and drug biotrans-
formation process (28). SNPs mutation were most com-
monly found in GSTT, GSTM, GSTA, and GSTP but null 
allele (i.e. GSTM1*0, GSTT1*0) which is known to have 
complete deletion of the gene only involves with GSTM 
and GSTT (28). Null allele affects the functions of en-
zyme more significantly than other allele variants. The 
Figure 1: GST classification. GST enzymes are subcategorized under 
two superfamilies; cytosolic/ soluble GST and MAPEG. Each gene 
(italic) encoding for respective superfamily enzyme is located on dis-
tinct chromosomal location in parenthesis. 
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loss of gene accounts for less production of gene prod-
ucts or enzyme as the gene-protein transcription process 
is blocked and results in a complete loss of enzymatic 
function (29).
Genetic Polymorphism of GSTM1 
GSTM has been expressed in liver and identified to have 
five isoenzyme subunits: GSTM1, GSTM2, GSTM3, 
GSTM4 and GSTM5 as shown in Fig.2 (19,30). Altogeth-
er, those genes clustered at chromosome 1p13.3 with 
the total size of 100-kb and the amino acid sequence 
similarity of 85% between each gene. Among the GSTM 
subunits, GSTM1, GSTM2, and GSTM3 show a high se-
quence similarity to GSTM4 with more than 70% (31). 
However, the catalytic efficiency of each gene was 
somehow determined to be significantly different. This is 
due to the evolution of the genes specifically in the GST 
binding sites to tackle a wide scope of substrates (32). 
Additionally, GSTM1 is the most abundant and highly 
polymorphic cytosolic GST, alongside GSTT1, GSTT2, 
GSTA1, GSTA2, and GSTP1 in human compared to oth-
er GSTM subunits, which makes it as the gene of interest 
in numerous physiological and pharmacological studies 
(33). 
codon 172, which are lysine and asparagine, respective-
ly (37). However, these two alleles are not functionally 
different from each other as both did not show any sig-
nificant contribution to the alteration of enzymatic func-
tion in any previous studies (28). Meanwhile, an overex-
pression of GSTM1 was presented in GSTM1*1X2 allele 
which resulted from gene duplication. Hence, this par-
ticular allele elevates the functionality of GST enzymes 
(12). Other than GSTM1, no studies have reported any 
deletion polymorphisms in other GSTM isoenzymes, 
specifically deletion of the entire gene, and its associa-
tion with reduced metabolic capacity. In regard to this, 
only GSTM1 have been investigated in large-scale stud-
ies and signified its significance in toxicology and can-
cer epidemiology studies. 
Genetic Polymorphism of GSTT1 
Two loci encode for GSTT had been identified to be 
clustered at chromosome 22q11.2 (38,39). The gene 
loci were denoted as GSTT1 and GSTT2 and separated 
by ~50kb. These two GSTT isoenzymes have ~55% ho-
mology which is less compared to other GST classes that 
have a range of 75-95% of sequence identity among the 
members of the same class (19,40). 
There are two 18kb flanking regions of more than 90% 
sequence identity (HA3 and HA5), situated downstream 
and upstream of GSTT1 as illustrated in Fig. 3. The dele-
tion polymorphism of GSTT1 (GSTT1*0) arise due to the 
homologous recombination between the 100% identical 
403bp sequences located in the center of both flanking 
regions (41). Consequently, GSTT1 enzymes are unable 
to be expressed and the enzymatic activity is lost due to 
the absence of the gene. 
Figure 2: Mechanism of GSTM1 polymorphism. GSTM1 is being 
located on chromosome 1 alongside other five GSTM subunits and 
embedded by two homologous regions (white box) in the normal/ 
wild-type allele. However, the null allele will be produced when ho-
mologous recombination between the two flanking regions occurs and 
GSTM1 gene is completely excised.
GSTM1 is located in between of GSTM2 and GSTM5 
and separated from these two genes by the presence 
of 4.2 kb homologous flanking regions at each side of 
the gene locus (9) as illustrated in Fig.2. The two flank-
ing regions are probable to recombine and result in the 
absence of 16-kb GSTM1 locus. The deletion polymor-
phism produces a null allele (GSTM1*0) and GSTM2 
will be subsequently located next to GSTM5 (34,35). 
However, the highly identical repeats between the two 
regions makes it difficult to determine the deletion junc-
tion. In addition, exon 8 of GSTM1 and GSTM2 genes 
have a high sequence similarity of 99% and an unequal 
crossing over has a high tendency to occur between the 
two gene loci to produce GSTM1*0 (19,36). The ab-
sence of the GSTM1 gene results in no expression of the 
enzymes.
Apart from GSTM1 null allele (GSTM1*0), GSTM1 has 
other 3 allelic variants which are GSTM1*A, GSTM1*B 
and GSTM1*1X2. A single nucleotide substitution at 
position 534 results in two alleles: GSTM1*A (G) and 
GSTM1*B (C) containing different amino acid product at 
Figure 3: Mechanism of GSTT1 polymorphism. GSTT1 and GSTT2 
are arranged on chromosome 22 and separated by two homogenous 
regions (HA3 and HA5) in the wild-type allele. Homologous recom-
bination is likely to occur between the highly identical sequence of 
the central portions of HA3 and HA5 which causes the gene locus of 
GSTT1 to be deleted n the null allele. 
Apart from GSTT1*0, GSTT1 also has other two func-
tional allelic variants which are GSTT1*A and GSTT1*B, 
involved in different catalytic activity (42). A single nu-
cleotide polymorphism (SNP) that substitutes amino 
acid 104 will produce two different alleles, GSTT1*A 
(threonine) and GSTT1*B (proline) and modify the en-
zymatic structure. It alters the level of enzymatic func-
tion with GSTT1*B showing lower catalytic activity than 
GSTT1*A (42). Unlike null allele, this SNP still results 
in enzymatic function because the polymorphism only 
occurs at a single base without interrupting the whole 
GSTT1 gene sequence and the enzyme can still be pro-
duced (42).
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Compared to GSTT1, GSTT2 has only two functional 
alleles: GSTT2*A (methionine) and GSTT2*B (isole-
ucine) that produce different products of amino acid 
139. However, the two alleles do not significantly af-
fect the enzymatic activity (42). This shows that GSTT1 
polymorphism is more significant due to its alteration in 
the enzyme metabolic capacity compared with GSTT2 
polymorphism. Since GSTT1*0 confers a complete loss 
of enzymatic activity and down regulates detoxification 
system, this null allele has been recognized as an im-
portant GST marker in toxicological and epidemiolog-
ical studies (43).
Frequency of GSTM1 and GSTT1 null polymorphism 
GSTM1 and GSTT1 have been observed to show eth-
nic dependent polymorphisms, where its occurs at dif-
ferent frequencies across populations. The frequency of 
GSTM1 null is higher in European with 50-57% and fol-
lowed by African (30-55%), Asian (28-66%) and Ameri-
can (44%) populations. GSTT1 null genotype is varying 
from 7%-53% for those of Asian descent; 29%-50% of 
African descent, 10%-33% of European descent and 
12%-18% of American descent (44).
Malaysia is a multiracial country comprising of diverse 
ethnic groups. Department of Statistic Malaysia reported 
for 2014-2016, Bumiputera are predominant in Malay-
sia with 68.6%, followed by Chinese (23.4%), Indians 
(7.0%) and others (1.0%) of the population (45). Bumi-
putera consists of Malays and indigenous peoples, in-
cluding Orang Asli, Dayak, Anak Negeri (45). To the 
best of our knowledge, there are only few studies report-
ing on GSTM1 and GSTT1 deletion in Malaysia. Nur-
fatimah et al., (2011) reported about 59.4% and 32% 
of Malaysians with deletion of GSTM1 and GSTT1, re-
spectively (46). Different study by Alshagga et al. (2011) 
revealed the deletion of GSTM1 occurs at 66% but the 
frequency of GSTT1 deletion is lower (18%) (47). How-
ever, these studies did not include the other two ma-
jor ethnic groups, which are the Chinese and Indian. In 
2012, Eshkoor et al. had determined GSTM1 (9.17%) 
and GSTT1 (62.5%) deletion in the control population 
that consisted of the three ethnic groups but did not 
further differentiate the null polymorphism in each eth-
nic groups (48). Thus, the relationship between the null 
polymorphism and ethnicity factor is still undetermined 
in Malaysia to date. Therefore, few studies have been 
selected from different populations and continents to 
highlight and compare the distribution of GSTM1 and 
GSTT1 null polymorphism between Malaysian and oth-
er populations (Table I). 
The frequency of GSTM1 deletion in Malaysian popu-
lation (59.4%) is similar to those reported in Tunisian 
(54.39%), Sudanese (54.4%) and German (57%) popu-
lations but higher than those reported in Iranian (28%), 
Indian (33.3%), and Nigerian (30%) (5,49–52). Mean-
while, the frequency of GSTT1 deletion in Malaysian 
population (32%) is consistent with Indian (24.4%) but 
Table I: Frequency of GSTM1 and GSTT1 null genotypes in Malay-
sian and worldwide populations. Null polymorphism of GSTM1 and 
GSTT1 are observed at different frequencies among the distinct pop-
ulations. The high frequency of GSTM1 null in Malaysian population 
is consistent with majority of the populations. Unlike GSTM1, the 
frequency of GSTT1 null appears to be diverged between Malaysian 
population and most of the populations. 
Popula-
tion
N Assay
Null genotype (%)
Reference
GSTM1 GSTT1
GSTM1/ 
GSTT1
Malay-
sian
128
Multi-
plex-PCR
59.4 32 16.4 (46)
Chinese 412
Duplex 
PCR
47.1 48.1 21.86 (57)
Iranian 336
Multiplex 
PCR
28.0 20.8 12.5 (5)
Turkish 231
Multiplex 
PCR
53.68 18.61 20.40 (56)
Indian 492
Multiplex 
PCR
33.3 24.4 7.9 (51)
Korean 244
Multiplex 
PCR
57.4 52.5 30.7 (4)
Tunisian 182
Multiplex 
PCR
54.39 29.12 18.68 (50
Nigerian 300
Multiplex 
PCR
30 37 13 (49)
Sudanese 114
Multiplex 
PCR
54.4 42.1 24.6 (53)
Moroc-
can
93
Multiplex 
PCR
40.9 9.7 5.4 (58)
Cauca-
sian
105
Multiplex 
PCR
56.2 21 16.2 (55)
Italian 548
Multiplex 
PCR
50.4 16.7 7.7 (54)
German 93
Real–Time 
PCR
57 18 10.8 (52)
Brazilian 147
Real-Time 
PCR
43.5 12.2 4.1 (59)
*N- number of control subjects; PCR-polymerase chain reaction
higher than in Iranian (21%), Turkish (18.61%), Cauca-
sian (21%) and Italian (16.7%) populations (5,51,53–56). 
However, Chinese and Korean populations have higher 
prevalence of GSTT1 null with 48.1% and 52.5%, re-
spectively (50,57). The occurrence of deletion polymor-
phism in both GSTM1 and GSTT1 genes in Malaysia is 
less common with the frequency at 16.4% only (46). 
It is in relatively higher than the frequency reported in 
Brazilian (4.1%), Moroccan (5.4%), Italian (7.7%), Indi-
an (7.9%) and German (10.8%) populations but lower 
than Koreans, which has the highest frequency at 30.7% 
(51,52,54,58,59).
The distribution patterns of GSTM1 and GSTT1 poly-
morphisms are illustrated in Fig. 4. GSTM1 gene is ob-
served to be absent in most of the populations at high 
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Figure 4: Distribution of GSTM1 and GSTT1 null genotype in world-
wide populations. Null polymorphism of GSTM1 and GSTT1 are ob-
served at different frequencies among the populations in four main 
continents. All four continents shows high frequencies of GSTM1 null 
whereas GSTT1 are commonly deleted in Asia and Africa only com-
pared in other two continents. The incidence of homozygous deletion 
of both genes is lower compared to the deletion of either one gene for 
each population.
therapy purpose (64). High GST activity will reduce the 
effectiveness of anticancer drugs and build up resistance 
towards chemotherapy agents (64).  The current alterna-
tive is to produce a suitable GST inhibitors which can 
work efficiently to achieve a good therapeutic index of 
the drugs (64).
Relevance of GST polymorphism to disease susceptibil-
ity
As the main character in detoxification of a wide range 
of carcinogens and toxicants from drugs or environment, 
GSTM1 and GSTT1 deletion could render individuals to 
be more susceptible to diseases or cancers due to abol-
ished enzymatic activity. Absence of the genes has been 
linked with several main cancers in a number of studies 
as shown in Table II. 
Nullity of GSTM1 and GSTT1 has been commonly 
found to be associated with increased risk of lung can-
cer (LC) as null individuals are hypothesized to be un-
able to detoxify the main carcinogens involved in the 
carcinogenesis such as benzo[α]pyrene, nitrosamine, 
and aromatic amines that present in tobacco smoke 
(6,65,66). Homozygous null genotype (-/-) of each gene 
was significantly emphasized to be a stronger candidate 
risk factor of LC through trimodal genotype analysis (+/-, 
+/-, -/-) in a Caucasian study (65). However, the delete-
rious effect of GSTs on LC could not be replicated in few 
studies. Both genes failed to be marked as the genetic 
factor to the cancer development in Bangladeshi popu-
lation whereas a South India study showed only GSTT1 
null individuals were susceptible to the cancer in the 
population (67,68). These contradicting findings might 
indicate the impact of ethnicity. However, small sample 
size and less detailed information about other risk fac-
tors (i.e. residential area and smoking status) in some of 
the studies, might also explain for the heterogeneity. In 
contrast, GSTT1 polymorphism showed a protective ef-
fect against the development of LC in North East Indian 
population (10). Gene-gene interaction is plausible to 
cause the null effect being masked by functional com-
pensation of GSTT1 null with other GST or metabolic 
genes. Despite its role in detoxification, GSTT1 also in-
volves in activation process of certain toxic compound 
which is advantageous for null individuals (69).
Reduction of GSTs’ enzymatic activity is also responsi-
ble to high risk of gastric cancer (GC) among individ-
uals with null genotype. GSTM1 and GSTT1 null gen-
otypes were considered as the potential risk modifiers 
for GC among the exposed group of Italians and Chi-
nese (70,71). However, such associations were unde-
termined in other case-control studies. Although a Ko-
rean study involved greater sample size and a similar 
study was conducted in Chinese population, both failed 
to prove the modification effect of GST polymorphisms 
on GC risk including in Spanish population (72–74). 
Other than ethnicity factor, selection of respondents in 
both cases and controls group might be the reason for 
frequency. In Asia continent, the deletion mutation in 
GSTT1 varies across the different countries, including 
Malaysia, compared in GSTM1 that makes the determi-
nation of GSTT1 status in Asia regions is difficult. Apart 
from the inter-ethnic differences, an evolutionary basis 
may contribute to the contrariety findings. Genetic drift 
may present in all populations; however, the effects of 
the evolutionary mechanism such as random sampling 
and bottleneck effect are likely to become obvious in 
some of small Asian populations (60,61), including Ma-
laysia. For example, the probability of the null alleles to 
be selected and passed down to the next generations in 
each population might be imbalanced, which is higher 
or lower in one population compared to other popula-
tions. Therefore, the genetic variation is most likely to 
appear between Asian countries. 
Significance of GSTM1 and GSTT1
As the dominant enzymes in detoxification system, gene 
expression of GSTs is important to resist a wide range of 
carcinogens and toxicants from drugs or environment. 
Deletion mutation is considered as minor polymor-
phism (<10%) that occurs in human population whereas 
single nucleotide polymorphisms (SNPs) (90%) are more 
common. However, deletion polymorphism showed to 
greatly affect carcinogen metabolism compared to SNPs 
(62). Thus, this explains the homozygous deletion of 
GSTM1 and GSTT1 have been intensively explored in 
more than 500 publications in molecular epidemiology 
(9). The deletion of the two genes is predicted to impair 
the detoxification of carcinogens in the body and the 
null individuals are exposed to high risk of cancers and 
diseases such as lung (6)  and gastric cancers (57). Thus, 
investigations on these particular genes can contrib-
ute beneficial values to the knowledge in genetics and 
cancer etiology. The knowledge can lead to the aware-
ness of the danger of environmental pollutants, drugs 
and dietary agents that presents in our daily life (63). 
However, there are certain situations where the level of 
GSTs needs to be down regulated such as for chemo-
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Table II: Association between GSTM1 and GSTT1 polymorphism and disease susceptibility worlwide. Null polymorphism of GSTM1 and GSTT1 
are observed to significantly modified the risk of cancers or diseases in some of the populations. Meanwhile, inverse associations were observed 
in few studies or populations.
Diseases Year Population
N
Matching Criteria Sample Genotyping Assay
Null genotype
Reference
Case
Con-
trol
GSTM1 GSTT1
Lung 
cancer
2012 Caucasian 2100 2120
Age, sex, and 
residential areas
Blood
Duplex TaqManR 
Real-Time PCR
↑ ↑ (66)
2014
Chinese 110 100
Age, sex, 
smoking status
Blood Multiplex PCR ↑ ↑ (67)
North 
East-Indian
154 154
Age, sex, 
smoking status
Blood Real-Time PCR - ↓ (10)
Bangladeshi 106 117
Age, sex, 
smoking status
Blood 
Duplex PCR
- - (69) 
2015 North Indian 270 270
Age, sex, 
smoking status
Blood Multiplex-PCR ↑ ↑ (6)
2016 South Indian 246 250
Age, sex, 
smoking 
Blood Multiplex PCR - ↑ (68)
Gastric 
cancer
2009 Korean 2213 1699
Age, sex, drinking, 
smoking status
Blood Real-Time PCR - - (73)
2010 Italian 314 548
Age, sex, H.pylori 
serology, family 
cancer history, 
residential area, 
smoking
Blood Multiplex PCR ↑ ↑ (72
2012 Spanish 557 557
Age, sex, and 
residence areas 
Blood Multiplex PCR - - (74)
2012 Chinese 410 410
Age, sex, H.pylori 
infection, smoking
Blood PCR-CTPP ↑ ↑ (71)
2017 Chinese 242 396
Age, sex, drinking, 
smoking, family 
cancer history and 
intake of pickled 
food.
Blood Multiplex PCR - - (75)
Diabetes 
Mellitus
2007 Turkish 98 98 NA Blood Real-Time PCR ↑ - (76)
2013 Brazilian 120 147
Age, sex, smoking, 
and drinking
Blood
Multiplex SYBR 
Green Real-Time PCR
- ↑ (59)
2016 Malaysian 151 136 Age, sex, ethnic Blood Multiplex PCR - - (77)
Colorectal 
cancer
2009 Korean 1829 1699
Age, sex, drinking, 
smoking status
Blood Real-Time PCR - - (73)
2011 Malaysian 111 128 NA Blood Multiplex PCR - ↑ (46)
2014 Chinese 264 317 Age and sex Blood Multiplex PCR ↑ ↑ (78)
2018 Polish 197 104 NA Blood
qPCR relative quanti-
fication method 
↑ ↑ (8)
Bladder 
cancer
2013 Turkish 114 114 Age, sex FFPE Multiplex PCR - ↑ (80)
2016 Pakistani 236 270
Age, sex, residen-
tial areas, smoking 
status
Blood Multiplex PCR ↑ ↑ (79)
2018 Algerian 175 188
Age, sex, and 
ethnicity
Blood Multiplex PCR ↑ ↑ (7)
Prostate 
cancer
2011 Iranian 168 336
Age and smoking 
status
Blood Multiplex PCR ↑ ↑ (5)
*N-number of volunteers; NA- Not available in original article; FFPE: Formallin fixed paraffin embedded (nontumoral bladder tissues); ↑ - Increased risk of the specific cancer;↓ - Reduced risk 
of the specific cancer; ‘-‘ - No association observed between the null polymorphisms and cancer
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the discrepancies. Most of the studies recruited hospi-
tal-based controls which produced high probability to 
involve individuals having defective genes due to other 
diseases. Moreover, risk of GC was heightened in the 
simultaneous analysis of GST polymorphism and other 
contributing factors: Helicobacter pylori (H.pylori) in-
fection, smoking, and alcohol drinking. Thus, lacking of 
the variables in the matching criteria produced biased 
results and unable to utilize conditional logistic regres-
sion models efficiently. 
A strong association between the occurrence of dia-
betes mellitus type 2 (T2DM) and GSTM1 and GSTT1 
polymorphism has also been observed as the oxidative 
stress products produced from the disease pathogenesis 
are unable to be detoxified by the enzymes (58,75). The 
modifying effect of GSTM1 null was reported in Turkish 
patients whereas, Brazillian patients were only affected 
by the absence of GSTT1 gene (58,75). Meanwhile, both 
genetic polymorphisms showed no association with risk 
of T2DM among Malaysians (76). With similar sample 
size and assay, conflicting findings between GSTM1 and 
GSTT1 null and T2DM pathogenesis could be attribut-
able by the ethnicity factor. Likelihood of variation at 
the two gene loci in each ethnic’s ancestry line and pre-
disposition to T2DM are different among ethnics.
Null variant in GSTM1 and GSTT1 has also been 
demonstrated to confer colorectal (CC), bladder (BC), 
and prostate cancer (PC) susceptibility in different pop-
ulations (5,7,8,77,78). However, some of the findings 
diverged considerably with other studies, causing such 
associations remain inconclusive to date. Even though 
the null genotypes were analysed in a large group of 
cases and controls, a Korean study revealed no strong 
relationship between the genetic polymorphism and CC 
(72). Meanwhile, only GSTT1 null signified elevated risk 
for CC susceptibility among Malaysian patients (46). In 
addition, GSTM1 null showed to have no impact for 
risk of BC in Turkish population compared to Pakistani 
and Algerian (79). These disparities for both cancer cas-
es may be due to the inappropriate logistic regression 
used for matched case-control study, which was uncon-
ditional logistic regression analysis. This analysis had 
shown weak precision of evaluation and hypothesis of 
the study when compared to conditional logistic regres-
sion analysis (80) (Kuo et al., 2018). 
To date, case-control studies on GST-associated diseas-
es in Malaysia is consider still relatively less investigate 
to the influence of GST polymorphism on those com-
mon cancers in the population. As Malaysia is a mul-
tiethnic country, it is relevant to conduct epidemiolog-
ical studies to further signify the impact of ethnicity on 
the risk of disease incidence. Considering all the factors 
mentioned above, this review calls for future epidemi-
ological or case-control studies in Malaysian and other 
populations to be well designed with appropriate study 
design, measurements or variables, sample size, geno-
typing assays, and statistical analysis to precisely deter-
mine the relevance of GST polymorphism on disease 
susceptibility. Thus, the need to analyse data combining 
from numerous studies to reach general consensus on 
the associations can be reduced.
Genotyping assay for GSTM1 and GSTT1 
Conventional PCR is widely employed in numerous 
fields such as forensic, medical genetics, species identi-
fication, genetic mutations and polymorphisms by rep-
licating a target fragment in a trace amount of DNA into 
billion copies (81). In the early years of GST genotyping, 
restricted fragment length polymorphism (RFLP)-PCR 
technique has been performed to genotype the possi-
ble allelic variants of GSTM1 (GSTM1*A, GSTM1*B and 
GSTM1*0) simultaneously (69). However, this approach 
become less popular as both GSTM1*A and GSTM1*B 
alleles showed insignificant compared to the null allele 
(GSTM1*0), which was found to affect the carcinogen 
metabolism significantly.
To reveal more than one genetic variant in a DNA sam-
ple robustly, multiplex PCR has been developed to am-
plify multiple target genes of interest in a single reaction, 
otherwise it would require several reactions preparation, 
use more reagents and time in single PCR (82). Over 
the years, this method has been applied in a large-scale 
of GSTM1 and GSTT1 studies and co-amplified with an 
internal control that known to be constitutively present 
in humans such as β-globin and Albumin (ALB) genes 
(3,83,84). 
Besides, real-time PCR is also a common tool used to gen-
otype the polymorphism of GSTM1 and GSTT1 genes. 
This assay offers detection on copy number changes of 
both GSTM1 or GSTT1 alleles and distinguish homo-
zygous wild type (+/+) or null (-/-), and heterozygous 
null (+/-) genotypes. For example, a case control study 
by Zhou et al. (2010) has successfully extrapolated the 
impact of heterozygosity of GSTM1 or GSTT1 on age-re-
lated cataract (ARC) by differentiating the carriers of one 
(+/-) and two (-/-) null alleles using the quantitative re-
al-time PCR (85). On the other perspective, the informa-
tion on heterozygosity status of the genes will be valu-
able in the view of Hardy-Weinberg equilibrium (HWE). 
The presence of genetic polymorphism could be use to 
investigate the evolutionary forces over the generations 
in a population. Contrary, conventional PCR exclusive-
ly determines the homozygous gene deletion in the ab-
sence of gene products but unable to discriminate the 
heterozygous (+/-) from wild type (+/+) genotype (86). 
However, genotyping of heterozygous deletion for both 
GSTM1 and GSTT1 is less significant because the effect 
of the genes appeared to be significant in homozygous 
null individuals (87). 
CONCLUSION
Modification on both GSTM1 and GSTT1 expression 
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could influence the biotransformation or detoxification 
of carcinogens. Different distribution of GSTM1 and 
GSTT1 polymorphisms are found between ethnic 
groups and across the population gives an insight of the 
human genetic diversity. Regards to the polymorphism 
consequences on the health status, GST could be serve 
as a marker to explain and predict inter-individual 
differences in cancer risks. It also contributes a valuable 
knowledge to medicine field in improving diagnostic 
and therapeutic strategies for the cancers. However, the 
epemiological studies should be executed using a well-
designed of study by taking consideration on gene-gene 
interaction, larger sample size, selection bias of case 
and control groups, other relevant contributing factors 
and appropriate genotyping assay to robustly extrapolate 
the associations between GST polymorphisms and 
multifactorial cancer susceptibility with an adequate 
statistical power. Conventional PCR-based assay is still 
a simple, inexpensive and common method to genotype 
the null variant solely to observe the deletion effects. Yet 
other approaches either different assays or modified-PCR 
are necessary to provide more meaningful information 
on HWE and detailing out the effect of gene-dosage on 
disease risks. As a multi-ethnics country, comprehensive 
studies should be conducted to determine the genetic 
differences related to cancer susceptibility on the basis 
of ethnicity in Malaysia and may lead to the personalized 
medicine.
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